Pages that link to "Q42924246"
Jump to navigation
Jump to search
The following pages link to Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes (Q42924246):
Displaying 50 items.
- Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome (Q26780488) (← links)
- Microglia activation and anti-inflammatory regulation in Alzheimer's disease (Q33943873) (← links)
- Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study (Q34024272) (← links)
- Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging (Q34094369) (← links)
- Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity (Q34218488) (← links)
- Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update (Q34286094) (← links)
- RAGE controls leukocyte adhesion in preterm and term infants (Q34636067) (← links)
- Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women (Q34981419) (← links)
- Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man. (Q35237455) (← links)
- Circulating S100A12 Levels Are Associated with Progression of Abdominal Aortic Calcification in Hemodialysis Patients (Q35935760) (← links)
- Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis (Q38634988) (← links)
- Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study (Q36091982) (← links)
- Serum soluble RAGE levels and carotid atherosclerosis: the Northern Manhattan Study (NOMAS). (Q36935766) (← links)
- RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases (Q36969021) (← links)
- The AGE/RAGE axis in diabetes-accelerated atherosclerosis. (Q37091107) (← links)
- RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. (Q37152947) (← links)
- Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases (Q37259863) (← links)
- Levels of Soluble Receptor for Advanced Glycation End Products in Acute Ischemic Stroke without a Source of Cardioembolism (Q37384595) (← links)
- Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis (Q37433970) (← links)
- Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications (Q37564063) (← links)
- Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus (Q37587674) (← links)
- RAGE and the pathogenesis of chronic kidney disease (Q37737557) (← links)
- Glycation in diabetic nephropathy (Q37801858) (← links)
- RAGE biology, atherosclerosis and diabetes (Q37860348) (← links)
- A novel improved therapy strategy for diabetic nephropathy (Q37986418) (← links)
- An update on advanced glycation endproducts and atherosclerosis (Q38001410) (← links)
- The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus. (Q38131032) (← links)
- The pathobiology of diabetic vascular complications--cardiovascular and kidney disease (Q38200957) (← links)
- Genetic variants in the receptor for advanced glycation end products (RAGE) gene were associated with circulating soluble RAGE level but not with renal function among Asians with type 2 diabetes: a genome-wide association study (Q38546484) (← links)
- Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension? (Q39158946) (← links)
- Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus. (Q40509446) (← links)
- High mobility group box 1 in diabetic nephropathy (Q41672019) (← links)
- Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy (Q41789363) (← links)
- Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy (Q42171678) (← links)
- Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases. (Q42176457) (← links)
- Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats (Q42537047) (← links)
- Soluble form of receptor for advanced glycation end-products (sRAGE): do sRAGE ligands or anti-sRAGE auto-antibodies interfere with sRAGE quantification? (Q47686708) (← links)
- Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes (Q47994395) (← links)
- Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes (Q51742202) (← links)
- Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. (Q53490356) (← links)
- Decreased plasma sRAGE levels in COPD: influence of oxygen therapy (Q57549422) (← links)
- Temporal reliability of serum soluble and endogenous secretory receptors for advanced glycation end-products (sRAGE and esRAGE) in healthy women (Q57610196) (← links)
- The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood (Q57718003) (← links)
- Targeted reduction of advanced glycation improves renal function in obesity (Q60545683) (← links)
- Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospectiv (Q62592896) (← links)
- Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes. (Q64912818) (← links)
- Soluble Forms of the Receptor for Advanced Glycation Endproducts (RAGE) in Periodontitis. (Q64944576) (← links)
- Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects (Q80478922) (← links)
- Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome (Q83143362) (← links)
- Soluble RAGE and malondialdehyde in type 1 diabetes patients without chronic complications during the course of the disease (Q83455635) (← links)